Verrica Pharmaceuticals Inc
NASDAQ:VRCA

Watchlist Manager
Verrica Pharmaceuticals Inc Logo
Verrica Pharmaceuticals Inc
NASDAQ:VRCA
Watchlist
Price: 0.4654 USD -5.12% Market Closed
Market Cap: 42.7m USD

Intrinsic Value

VRCA's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one VRCA stock under the Base Case scenario is 1.1584 USD. Compared to the current market price of 0.4654 USD, Verrica Pharmaceuticals Inc is Undervalued by 60%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

VRCA Intrinsic Value
1.1584 USD
Undervaluation 60%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Verrica Pharmaceuticals Inc

VRCA
Valuation History
HIDDEN
Show
Valuation History Unavailable

Historical valuation for VRCA cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
0%

Fundamental Analysis

Verrica Pharmaceuticals Inc
NASDAQ:VRCA
US
Pharmaceuticals
Market Cap
42.7m USD
IPO
Jun 15, 2018
US
Pharmaceuticals
Market Cap
42.7m USD
IPO
Jun 15, 2018
Price
$false
EPS
$false
Company Overview
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about VRCA?
Bearish
Neutral
Bullish
AI Assistant
AI Assistant
Ask me anything about Verrica Pharmaceuticals Inc
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
Verrica Pharmaceuticals Inc

Current Assets 51.2m
Cash & Short-Term Investments 46.3m
Receivables 77k
Other Current Assets 4.8m
Non-Current Assets 3m
PP&E 2.6m
Other Non-Current Assets 376k
Efficiency

Free Cash Flow Analysis
Verrica Pharmaceuticals Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Verrica Pharmaceuticals Inc

Revenue
7.6m USD
Cost of Revenue
-2.7m USD
Gross Profit
4.8m USD
Operating Expenses
-70.7m USD
Operating Income
-65.8m USD
Other Expenses
-10.7m USD
Net Income
-76.6m USD
Fundamental Scores

VRCA Profitability Score
Profitability Due Diligence

Verrica Pharmaceuticals Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.

Exceptional Revenue Growth Forecast
Positive Gross Profit
Exceptional 1-Year Revenue Growth
Declining ROE
21/100
Profitability
Score

Verrica Pharmaceuticals Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.

VRCA Solvency Score
Solvency Due Diligence

Verrica Pharmaceuticals Inc's solvency score is 38/100. The higher the solvency score, the more solvent the company is.

Low D/E
Negative Net Debt
Short-Term Solvency
Long-Term Solvency
38/100
Solvency
Score

Verrica Pharmaceuticals Inc's solvency score is 38/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

VRCA Price Targets Summary
Verrica Pharmaceuticals Inc

Wall Street analysts forecast VRCA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for VRCA is 3.4 USD with a low forecast of 2.02 USD and a high forecast of 5.25 USD.

Lowest
Price Target
2.02 USD
334% Upside
Average
Price Target
3.4 USD
631% Upside
Highest
Price Target
5.25 USD
1 028% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Verrica Pharmaceuticals Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for VRCA is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

VRCA Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one VRCA stock?

The intrinsic value of one VRCA stock under the Base Case scenario is 1.1584 USD.

Is VRCA stock undervalued or overvalued?

Compared to the current market price of 0.4654 USD, Verrica Pharmaceuticals Inc is Undervalued by 60%.

Back to Top